Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine

被引:40
作者
Edelman, KJ [1 ]
He, QS
Makinen, JP
Haanpera, MS
Minh, NNT
Schuerman, L
Wolter, J
Mertsola, JA
机构
[1] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland
[2] Natl Publ Hlth Inst, Dept Human Microbial Ecol & Inflammat, Turku, Finland
[3] GlaxoSmithKline Biol, Rixensart, Belgium
关键词
D O I
10.1086/421943
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We evaluated pertussis-specific cell-mediated immunity (CMI) and humoral immunity in adolescents 3 years after they received an acellular pertussis booster immunization. Two hundred sixty-four adolescents were examined for immunoglobulin G antibodies, and 49 were examined for CMI against Bordetella pertussis antigens 40 months after receiving the booster. A control group of similarly aged adolescents who had received diphtheria and tetanus vaccination 3 years earlier was included for comparison. Pertussis-specific CMI persisted at greater than prebooster immunization levels. Although they had decreased by the 3-year follow-up, antibody levels remained significantly higher than prebooster immunization levels. Antibodies against pertussis antigens and CMI against filamentous hemagglutinin and pertactin were significantly higher in vaccinated adolescents than in control subjects. The acellular pertussis booster immunization provides long-term CMI and humoral immunity lasting for greater than or equal to3 years. The significantly higher immunity observed in the diphtheria, tetanus, and acellular pertussis vaccine recipients, compared with that in control subjects, indicates that these responses are more likely to have resulted from the booster immunization than from the boosting effects of natural B. pertussis infection.
引用
收藏
页码:179 / 185
页数:7
相关论文
共 35 条
  • [31] Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis
    Taranger, J
    Trollfors, B
    Lagergård, T
    Sundh, V
    Bryla, DA
    Schneerson, R
    Robbins, JB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) : 1010 - 1013
  • [32] A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults
    Turnbull, FM
    Heath, TC
    Jalaludin, BB
    Burgess, MA
    Ramalho, AC
    [J]. VACCINE, 2000, 19 (06) : 628 - 636
  • [33] A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults
    Van der Wielen, M
    Van Damme, P
    Joossens, E
    François, G
    Meurice, F
    Ramalho, A
    [J]. VACCINE, 2000, 18 (20) : 2075 - 2082
  • [34] The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998
    Yih, WK
    Lett, SM
    des Vignes, FN
    Garrison, KM
    Sipe, PL
    Marchant, CD
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05) : 1409 - 1416
  • [35] Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine
    Zepp, F
    Knuf, M
    Habermehl, P
    Schmitt, HJ
    Rebsch, C
    Schmidtke, P
    Clemens, R
    Slaoui, M
    [J]. INFECTION AND IMMUNITY, 1996, 64 (10) : 4078 - 4084